Asparaginases: Biochemical pharmacology and modes of drug resistance

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2423-2437

  Avramis, Vassilios I ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Acute lymphoblastic leukemia; Amino acid; Antibody; Asparaginase; Asparagine synthetase; Clinical outcomes; Crystalline structures of proteins; Drug resistance; Epitopes; Glutamine synthetase; Review

Indexed keywords

ASPARAGINASE; ASPARTATE AMMONIA LIGASE; CATHEPSIN B; CLADRIBINE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; GEMCITABINE; GLUTAMATE AMMONIA LIGASE; GLUTAMINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; IMATINIB; LEGUMAIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; MYC PROTEIN; ORNITHINE DECARBOXYLASE; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROTEIN BCL 2; RECOMBINANT DNA; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; T LYMPHOCYTE RECEPTOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGIC REACTION; ANAPHYLAXIS; APOPTOSIS; AREA UNDER THE CURVE; BLOOD CLOTTING FACTOR DEFICIENCY; BONE MARROW; BRAIN DYSFUNCTION; BRONCHOSPASM; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RISK; CELL DEATH; CELL SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DRUG DETERMINATION; DRUG ELIMINATION; EDEMA; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; ESCHERICHIA COLI; EVENT FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC DISORDER; GLUCOSURIA; HELA CELL; HEMATOPOIETIC STEM CELL; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPOALBUMINEMIA; HYPOFIBRINOGENEMIA; IC 50; IMMUNE RESPONSE; IN VIVO STUDY; KETOACIDOSIS; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; LIMB SWELLING; LIVER DYSFUNCTION; MANTLE CELL LYMPHOMA; MICROENVIRONMENT; MOLECULAR WEIGHT; NONHUMAN; NUTRIENT; ONCOGENE C FOS; ONCOGENE C JUN; PANCREATITIS; PECTOBACTERIUM CHRYSANTHEMI; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PRURITUS; RASH; REVIEW; SERUM SICKNESS; SIDE EFFECT; T CELL LYMPHOMA; UPREGULATION; URTICARIA;

ADOLESCENT; ASPARAGINASE; CHILD; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, T-CELL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; YOUNG ADULT;

EID: 84865679567     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds.).: SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
2. Gaynon PS: Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 131(5): 579-587, 2005.
3. Pui CH: Toward a total cure for acute lymphoblastic leukemia. J Clin Oncol 27(31): 5121 -5123, 2009.
4. Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G, Janka-Schaub GE, Kamps W, Masera G, Sallan S, Tsuchida M and Vilmer E: Long-term results of large prospective trials in childhood acute lymphoblastic leukemia 14(12): 2193-2194, 2000.
5. McLean SR, Gana-Weisz M, Hartzoulakis B, Frow R, Whelan J, Selwood D and Boshoff C: Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Mol Cancer Ther 4(12): 2008-2015, 2005. (Pubitemid 43056984)
6. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB. ABL protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-KIT and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1): 139-145, 2000.
7. Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE and Holcenberg JS: Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia. Cancer Res 47(24 Pt 1): 6786- 6792, 1987.
8. Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W and Kantarjian H: Clofarabine in leukemia. Expert Rev Hematol. 3(1):15-22, 2010.
9. Kidd JG: Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. II. Studies on the nature of the active serum constituent: histological mechanism of the regression: \Tests for effects of guinea pig serum on lymphoma cells in vitro: discussion. J Exp Med 98(6): 583-606, 1953.
10. Broome JD: Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med 118: 99-120, 1963.
11. Broome JD: Antilymphoma activity of L-asparaginase in vivo: clearance rates of enzyme preparations from guinea pig serum and yeast in relation to their effect on tumor growth. J Natl Cancer Inst 35(6): 967-974, 1965.
12. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS and Stork L: A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol-conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99(6): 1986-1994, 2002. (Pubitemid 34525479)
13. Avramis VI and Panosyan EH: Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 44(4): 367-393, 2005. (Pubitemid 40663683)
14. Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AM, Periclou AP and Avramis VI: Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 109(7): 2744-2750, 2007. (Pubitemid 46482066)
15. Nandy P, Periclou AP and Avramis VI: The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis. Anticancer Res 18(2A): 727-737, 1998. (Pubitemid 28239587)
16. Wadhwa W, Bird C, Dilger P, Gaines-Das R and Thorpe R: Strategies for detection, measurement, and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods 278: 1-17, 2003. (Pubitemid 37281188)
17. Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, Franklin J, Nachman J, Ettinger L, La M, Steinherz P, Cohen LJ, Siegel SE and Avramis VI: Children's Cancer Group Study CCG-1961. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 26(4): 217-226, 2004. (Pubitemid 38500969)
18. Jousse C, Bruhat A, Harding HP, Ferrara M, Ron D and Fafournoux P: Amino acid limitation regulates CHOP expression through a specific pathway independent of the unfolded protein response. FEBS Lett 448(2-3): 211-216, 1999. (Pubitemid 29168490)
19. Rotoli BM, Uggeri J, Dall'Asta V, Visigalli R, Barilli A, Gatti R, Orlandini G, Gazzola GC and Bussolati O: Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells. Cell Physiol Biochem 15(6): 281-292, 2005. (Pubitemid 41022630)
20. Gingras AC, Raught B and Sonenberg N: eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68: 913-963, 1999. (Pubitemid 29449212)
21. Fine BM, Kaspers GJ, Ho M, Loonen AH and Boxer LM: A genome-wide view of the in vitro response to asparaginase in acute lymphoblastic leukemia. Cancer Res 65(1): 291-299, 2005. (Pubitemid 40070821)
22. Ron D: Translational control in the endoplasmic reticulum stress response. J Clin Invest 110(10): 1383-1388, 2002.
23. Majlessipour F, Kwock R, Martin-Aragon S, Weinberg KI and Avramis VI: Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities. Anticancer Res 21(1A): 11-22, 2001. (Pubitemid 32267619)
24. Majlessipour F, Avramis IA, Kwock R, Weinberg KI and Avramis VI: The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines. Anticancer Res 22(3): 1361-1368, 2002. (Pubitemid 34839139)
25. DeBerardinis RJ, Lum JJ, Hatzivassiliou G and Thompson CB: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7(1): 11-20, 2008.
26. Paquette, JC, Guérin, PJ, and Gauthier ER: Rapid Induction of the Intrinsic Apoptotic Pathway by L-Glutamine Starvation. J Cell Physiol 202: 912-921, 2005. (Pubitemid 40175869)
27. Teachey DT, Grupp SA and Brown VI.: Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 145(5): 569-580, 2009.
28. Holleman A, Cheok MH, den Boer ML,Yang W, Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH and Relling MV, Janka-Schaub GE, Pieters R and Evans WE: Gene expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351: 533-542, 2004.
29. Holleman A, den Boer ML, de Menezes RX, Cheok MH, Cheng C, Kazemier KM, Janka-Schaub GE, Göbel U, Graubner UB, Evans WE and Pieters R: The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 107(2): 769-776, 2006. (Pubitemid 43076404)
30. Iwamoto S, Mihara K, Downing JR, Pui CH and Campana D: Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 117(4): 1049-1057, 2007. (Pubitemid 46556761)
31. Behan JW, Yun JP, Proektor MP, Ehsanipour EA, Arutyunyan A, Moses AS, Avramis VI, Louie SG, Butturini A, Heisterkamp N and Mittelman SD: Adipocytes impair leukemia treatment in mice. Cancer Res 69(19): 7867-7874, 2009.
32. Tardito S, Chiu M, Uggeri J, Zerbini A, Da Ros F, Dall'Asta V, Missale G and Bussolati O: L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets 11(8): 929-943, 2011.
33. Holcenberg JS and Teller DC: Physical properties of antitumor glutaminase-asparaginase from Pseudomonas 7A. J Biol Chem 251(17): 5375-5380, 1976.
34. Ding Y, Li Z and Broome JD: Epigenetic changes in the repression and induction of asparagine synthetase in human leukemic cell lines. Leukemia 19(3): 420-426, 2005. (Pubitemid 40403320)
35. Andrulis IL and Barrett MT: DNA methylation patterns associated with asparagine synthetase expression in asparagine-overproducing and -auxotrophic cells. Mol Cell Biol 9(7): 2922-2927, 1989. (Pubitemid 19163055)
36. Guerrini L, Gong SS, Mangasarian K and Basilico C: Cis- and trans-acting elements involved in amino acid regulation of asparagine synthetase gene expression. Mol Cell Biol 13(6): 3202-3212 & 3234-3237, 1993.
37. Barbosa-Tessmann IP, Chen C, Zhong C, Siu F, Schuster SM, Nick HS and Kilberg MS: Activation of the human asparagine synthetase gene by the amino acid response and the endoplasmic reticulum stress response pathways occurs by common genomic elements. J Biol Chem 275(35): 26976-26785, 2000.
38. Siu F, Bain PJ, LeBlanc-Chaffin R, Chen H and Kilberg MS: ATF4 is a mediator of the nutrient-sensing response pathway that activates the human asparagine synthetase gene. J Biol Chem 277(27): 24120-24127, 2002. (Pubitemid 34951925)
39. Gong SS, Guerrini L and Basilico C: Regulation of asparagine synthetase gene expression by amino acid starvation. Mol Cell Biol 11(12): 6059-6066, 1991. (Pubitemid 21895377)
40. Guerrini L, Gong SS, Mangasarian K and Basilico C: Cis- and trans-acting elements involved in amino acid regulation of asparagine synthetase gene expression. Mol Cell Biol 13(6): 3202-3212, 1993. (Pubitemid 23157258)
41. Grigoryan RS, Panosyan EH, Seibel NL, Gaynon PS, Avramis IA and Avramis VI: Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In Vivo 18(2): 107-112, 2004. (Pubitemid 38488992)
42. Avramis VI and Spence SA: Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. J Pediatr Hematol Oncol 29(4): 239-247, 2007. (Pubitemid 46597688)
43. Avramis VI, Martin-Aragon S, Avramis EV and Asselin BL: Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models. Anticancer Res 27(4C): 2561-2572, 2007. (Pubitemid 47227966)
44. Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK, Wang B, Pui CH and Relling M: Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 12(10): 1527-1533, 1998. (Pubitemid 28470435)
45. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK, Rubnitz JE, Harrison PL, Wang B, Evans WE, Pui CH and Relling MV: Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 18(7): 1525-1532, 2000. (Pubitemid 30205399)
46. Wang B, Relling MV, Storm MC, Woo MH, Ribeiro R, Pui CH and Hak LJ: Evaluation of immunologic cross-reaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 17(8): 1583-1588, 2003. (Pubitemid 36992159)
47. Liu C, Kawedia JD, Cheng C, Pei D, Fernandez CA, Cai X, Crews KR, Kaste SC, Panetta JC, Bowman WP, Jeha S, Sandlund JT, Evans WE, Pui CH and Relling MV: Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia Apr 9 2012. doi: 10.1038/leu.2012.102. [Epub ahead of print].
48. Kawedia JD, Liu C, Pei D, Cheng C, Fernandez CA, Howard SC, Campana D, Panetta JC, Bowman WP, Evans WE, Pui CH and Relling MV: Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 119(7): 1658-1664, 2012.
49. Meiser A (Ed.).: Biochemistry of Amino Acids, 2nd edn. Vol. 1. Academic Press, New York, pp. 457-460 1965.
50. Horowitz B, Madras BK, Meister A, Old LJ, Boyes EA and Stockert E: Asparagine synthetase activity of mouse leukemias. Science 160(827): 533-535, 1968.
51. Horowitz B and Meister A: Glutamine-dependent asparagine synthetase from leukemia cells. Chloride dependence, mechanism of action, and inhibition. J Biol Chem 247(20): 6708-6719, 1972.
52. Aghaiypour K, Wlodawer A and Lubkowski J: Structural basis for the activity and substrate specificity of Erwinia chrysanthemi L-asparaginase. Biochemistry 40(19): 5655-5664, 2001. (Pubitemid 32440869)
53. Kotzia GA and Labrou NE: L-Asparaginase from Erwinia chrysanthemi 3937: cloning, expression and characterization. J Biotechnol 127(4): 657-669, 2007. (Pubitemid 44959113)
54. Müller HJ, Löning L, Horn A, Schwabe D, Gunkel M, Schrappe M, von Schütz V, Henze G, Casimiro da Palma J, Ritter J, Pinheiro JP, Winkelhorst M and Boos J: Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol 110(2): 379-384, 2000.
55. Müller HJ, Beier R, da Palma JC, Lanvers C, Ahlke E, von Schütz V, Gunkel M, Horn A, Schrappe M, Henze G, Kranz K and Boos J: PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemother Pharmacol 49(2): 149-154, 2002.
56. Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH and Avramis VI: Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 10(16): 5335-5341, 2004. (Pubitemid 39100468)
57. Jarrar M, Gaynon PS, Periclou AP, Fu C, Harris RE, Stram D, Altman A, Bostrom B, Breneman J, Steele D, Trigg M, Zipf T and Avramis VI: Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer 47(2): 141-146, 2006. (Pubitemid 44025245)
58. Lee JI, Dominy JE Jr., Sikalidis AK, Hirschberger LL, Wang W and Stipanuk MH: HepG2/C3A cells respond to cysteine deprivation by induction of the amino acid deprivation/integrated stress response pathway. Physiol Genomics 33(2): 218-229, 2008. (Pubitemid 351629530)
59. Estes DA, Lovato DM, Khawaja HM, Winter SS and Larson RS: Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples. Br J Haematol 139(1): 20-30, 2007. (Pubitemid 47389934)
60. Stams WA, den Boer ML, Beverloo HB, van Wering ER and Pieters R: Up-regulation of asparagine synthetase and cell cycle arrest in t(12;21)-positive ALL. Leukemia 19(2): 318-319, 2005; author reply: 319-321, 2005.
61. Appel IM, den Boer ML, Meijerink JP, Veerman AJ, Reniers NC and Pieters R: Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood 107(11): 4244-4249, 2006. (Pubitemid 43801347)
62. Stams WA, den Boer ML, Beverloo HB, Meijerink JP, Stigter RL, van Wering ER, Janka-Schaub GE, Slater R and Pieters R: Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood 101(7): 2743-2747, 2003. (Pubitemid 36857638)
63. Capizzi RL: Asparaginase revisited. Leuk Lymphoma 10 Suppl: 147-150, 1993.
64. Albertsen BK, Schrøder H, Ingerslev J, Jakobsen P, Avramis VI, Müller HJ, Carlsen NT and Schmiegelow K: Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol 115(4): 983-990, 2001. (Pubitemid 34042920)
65. Albertsen BK, Schrøder H, Jakobsen P, Avramis VI, Müller HJ, Schmiegelow K and Carlsen NT: Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 38(5): 310-316, 2002. (Pubitemid 34493110)
66. Avramis VI, Avramis EV, Hunter W and Long MC: Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res 29(1): 299-302, 2009.
67. Avramis VI and Tiwari PN: Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine 1(3): 241-254, 2006.
68. Moola ZB, Scawen MD, Atkinson T and Nicholls DJ: Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes. Biochem J 302 (Pt 3): 921-927, 1994. (Pubitemid 24289334)
69. Werner A, Röhm KH and Müller HJ: Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment. Biol Chem 386(6): 535-540, 2005. (Pubitemid 41460232)
70. Billett AL, Carls A, Gelber RD and Sallan SE: Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 70(1): 201-206, 1992.
71. Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L, Kelly KM, Laverdière C, Michon B, Schorin M, Cohen HJ, Sallan SE and Silverman LB: Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 54(2): 199-205, 2010.
72. Scawen MD, Atkinson T and Nicholls DJ: Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes. Biochem J 302(Pt 3): 921-927, 1994. (Pubitemid 24289334)
73. Maita T and Matsuda G: The primary structure of L-asparaginase from Escherichia coli . Hoppe Seylers Z Physiol Chem 361(2): 105-117, 1980. (Pubitemid 10122209)
74. Patel N, Krishnan S, Offman MN, Krol M, Moss CX, Leighton C, van Delft FW, Holland M, Liu J, Alexander S, Dempsey C, Ariffin H, Essink M, Eden TO, Watts C, Bates PA and Saha V: A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. J Clin Invest 119(7): 1964-1973, 2009.
75. Avramis VI: Asparaginases: a successful class of drugs against leukemias and lymphomas. J Pediatr Hematol Oncol 33(8): 573-579, 2011.
76. Abshire TC, Pollock BH, Billett AL, Bradley P and Buchanan GR: Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 96(5): 1709-1715, 2000. (Pubitemid 30661053)
77. Labrou NE, Papageorgiou AC and Avramis VI: Structure-function relationships and clinical applications of L-asparaginases. Curr Med Chem 17(20): 2183-2195, 2010.
78. Offman MN, Krol M, Patel N, Krishnan S, Liu J, Saha V and Bates PA: Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. Blood 117(5): 1614-1621, 2011.
79. Chronopoulou EG and Labrou NE: Site-saturation mutagenesis: a powerful tool for structure-based design of combinatorial mutation libraries. Curr Protoc Protein Sci. Chapter 26:Unit 26.6 Feb; 2011.
80. Papageorgiou AC, Posypanova GA, Andersson CS, Sokolov NN and Krasotkina J: Structural and functional insights into Erwinia carotovora L-asparaginase. FEBS J 275(17): 4306-4316, 2008.
81. Ramya LN, Mukesh D, Rekha PB and Pulicherla KK: In silico Engineering of L-Asparaginase to Have Reduced Glutaminase Side Activity for Effective Treatment of Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol 33(8): 617-621, 2011.
82. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE and Cohen HJ: Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 11(9): 1780-1786, 1993. (Pubitemid 23277332)
83. Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH and Camitta BM: Polyethylene glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). J Pediatr Hematol Oncol 33(8): 610-616, 2011.
84. Salzer W, Asselin B, Supko J, Devidas M, Kaiser N, Plourde PV, Winick N, Reaman G, Raetz E, Carroll W and Hunger S: Administration of Erwinia asparaginase (Erwinase®) following allergy to PEG-asparaginase in children and young adults with acute lymphoblastic leukemia treated on AALL07P2 achieves therapeutic Nadir serum asparaginase activity: A report from the children's oncology group (COG). In: Proceedings of 52nd ASH Annual Meeting and Exposition, Abstr# 2134, presented in December at ASH-2010, Orlando, FL, Blood, November 19, 116, p. 882, 2010.
85. Gurbaxani B: Mathematical modeling as accounting: Predicting the fate of serum proteins and therapeutic monoclonal antibodies. Clin Immunol 122(2): 121-124, 2007.
86. Jakobsen CG, Bodtger U, Kristensen P, Poulsen LK and Roggen EL: Isolation of high-affinity human IgE and IgG antibodies recognising Bet v 1 and Humicola lanuginosa lipase from combinatorial phage libraries. Mol Immunol 41(10): 941-953, 2004. (Pubitemid 39070323)
87. Lofgren JA, Dhandapani S, Pennucci JJ, Abbott CM, Mytych DT, Kaliyaperumal A, Swanson SJ and Mullenix MC: Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol 178(11): 7467-7472, 2007. (Pubitemid 46847475)